- Email: [email protected]
Kudos Corner
K
U
D
O
S
C
O
R
N
E
R
Harvey L. Bumpers, MD, FACS The Editorial Board of the Journal of the National Medical Association has dedicated this column in recognition of the outstanding academic, scientific, social and cultural accomplishments of NMA members in all aspects of the medical profession. It is anticipated that these members will serve as both an inspiration to our young members and as a “road map” to assist them in planning for a successful career. Interested members are encouraged to contact the honorees directly. Submissions for this column are encouraged and should be forwarded to [email protected].
© 2008. From Surgical Oncology and Breast Services, Morehouse School of Medicine, Atlanta, GA. Send correspondence and reprint requests for J Natl Med Assoc. 2008;100:703–704 to: Dr. Harvey L. Bumpers, Professor of Surgery, Director of Surgical Oncology and Breast Services, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310; phone: (404) 616-2509; fax: (404) 616-1417; e-mail: [email protected]
D
r. Harvey Bumpers, professor of Surgery at Morehouse School of Medicine, Atlanta, GA, recently received two peer-review research awards from the Department of Defense and National Institutes of Health totaling nearly $1 million over three years.
Grant # 1 Department of Defense grant BC074381. This is an “Idea Award” with Bumpers as the principal investigator. His coinvestigators are Vincent Bond, PhD, and Ming-Bo Huang, MD. Title. Effects of a Viral Peptide (Nef) on Growth and Metastasis of Human Breast Cancer Description. This study will assess the ability of a novel peptide, Nef M1, to inhibit the growth and metastasis of breast cancer xenografts derived from cell lines and surgical specimens and implanted in severe combined immunodeficient (SCID) mice. This three-year award was issued on December 25, 2007 in the amount of $420,000 in total direct and indirect costs. Translational benefit of this research. By using this peptide to bind and replace the natural ligand for the cxcr-4 receptors on breast cancer cells, apoptosis can be induced within the tumor. This has been demonstrated both in human breast cancer cell lines and tumors derived from those cell lines. Bumpers was one of the first investigators in the world to develop the capability of propagating human surgical specimens of human breast cancer in SCID mice and demonstrated that this can be studied for both tumor engraftment and patterns of metastasis. This can potentially translate to adjuvant or combination therapy for breast cancer. The grant will enable the investigators to study the effect of this peptide on the primary growth of breast cancer as well as its ability to inhibit metastasis, specifically evaluating spread of disease to the liver and lungs. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
Grant # 2 Morehouse School of Medicine (MSM) & the University of Alabama–Birmingham Cancer Center (UABCCC) Partnership, National Institutes of Health U542-U54CA118948 This grant funds a partnership between MSM and UABCCC. Each institution is represented by a project or pilot grant principal investigator. The principal investigators on this grant are Dr. Upender Manne at UAB and Bumpers at MSM. (Cooperative cancer initiatives between these institutions have been underway for several years, and this award is the culmination of Bumpers’ lifelong interest in this area and this productive joint venture. Title. Predictive Molecular Markers of Colorectal Cancer of African-American Patients Description. The studies proposed in this project will identify potential prognostic phenotypic molecular markers of African Americans with colon cancer. This three-year award was approved on September 30, 2007, for a total direct and indirect cost of $423,000. Translational benefit of this research. In preliminary studies, Manne has shown that colorectal cancer in some African Americans manifests a preponderance of certain tumor markers. There was a strong correlation with the response to 5FU-based chemotherapy (5FU + leucovorin or 5FU + leucovorin + oxaliplatin), tumor phenotypes (Bcl-2, Bax, p53, etc.) and survival (in AfriVOL. 100, NO. 6, JUNE 2008 703
HARVEY L. BUMPERS, MD, FACS
can Americans, that was different from the same treatment algorithms utilized in Caucasians). Based on this preliminary research, the chemotherapy regimens used in Caucasians to treat colorectal cancers, sporadic stageII and -III, may actually be detrimental to survival in African Americans with similar phenotypic tumors and vice versa. Thus, this research could lead to routine evaluation of tumor phenotypes in African Americans with colorectal cancer, and therapy can be tailored specifically to those tumors based upon the known response patterns of these agents. At the present time, due to the lack of minority patients’ recruitment and participation in trials, it is assumed that all outcomes for treatment will be the same for African Americans and Caucasians with similar cancer diagnoses, and preliminary data suggest that this may not be the case. *** Bumpers was born in Mobile, AL, in 1956, attended Trinity College in Hartford, CT, from 1974–1978, graduating with a BS in biology followed by his MD degree with distinction in research from the University of Rochester in 1982. His surgical residency at the State University of New York at Stonybrook from 1982–1989 included two years as a cancer research fellow under Dr. Herbert Hoover. This was followed by a two-year clinical surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, NY. He then joined the faculty at the State University of New York at Buffalo as assistant professor of surgery from 1991–1996, and during that period he spent committed research time in the laboratory of Dr. Richard B. Bankert, who was the director of immunology at Roswell Park Cancer Institute. In 1996, Bumpers assumed the position of vice chairman of surgery and associate program director in surgery at MSM, where he remains today. Bumpers is certified by the American Board of Surgery with added qualifications in gastrointestinal endoscopic surgery. He is a faculty member of Alpha Omega Alpha; a fellow of the American College of Surgeons;
and a member of the American Association for Cancer Research, the Society of Surgical Oncology, the American Society of Clinical Oncology, the Society of American Gastrointestinal Endoscopic Surgeons, the Association for Academic surgery, the Society of Black Academic Surgeons and the Surgical Section–National Medical Association, among many others. He has been selected as Physician of the Year at Grady Hospital and has earned the Surgical Residency Teacher’s Award at Morehouse as well as the Teaching Excellence Award granted by the senior class at SUNY–Buffalo and the Student National Medical Association Teaching Award at SUNY–Buffalo in 1996. Bumpers has published 42 manuscripts in peerreviewed journals, book chapters and numerous abstracts and presentations across the country in his areas of expertise of breast and colon cancer. He has mentored countless students and residents during his career. Bumpers was the first investigator in the world to successfully implant a human breast cancer into an animal (SCID) mouse model in which the tumor actually engrafted, grew and metastasized, thus providing a reproducible model to study both the engraftment of tumors as well as their patterns of metastasis. He holds two patents, one for the SCID mouse model noted above and another for the viral peptide, Nef, that is the subject of the Department of Defense award below. He recently received two peer-review grants: 1) Department of Defense grant BC 074381 for $420,000 over three years to study the “effects of a viral peptide (Nef) on growth and metastasis of human breast cancer in a SCID mouse model” with colleague Bond; and 2) an NIH partnership award between the UABCCC, MSM School of medicine and Tuskegee, NIH U542-U54CA118948, for $423,000 over three years to evaluate, “the predictive molecular markers of colorectal cancer for African American patients” with UAB colleague Manne. Bumpers is married to Shari Bumpers, and they have three children. Bumpers has been very active in the Atlanta community educating the population at large about cancer prevention and treatment.
We Welcome Your Comments
To photocopy, e-mail, post on Internet or distribute this or any part of JNMA, please visit www.copyright.com.
704 JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
The Journal of the National Medical Association welcomes your Letters to the Editor about articles that appear in the JNMA or issues relevant to minority healthcare. Address correspondence to [email protected].
VOL. 100, NO. 6, JUNE 2008
U
D
O
S
C
O
R
N
E
R
Harvey L. Bumpers, MD, FACS The Editorial Board of the Journal of the National Medical Association has dedicated this column in recognition of the outstanding academic, scientific, social and cultural accomplishments of NMA members in all aspects of the medical profession. It is anticipated that these members will serve as both an inspiration to our young members and as a “road map” to assist them in planning for a successful career. Interested members are encouraged to contact the honorees directly. Submissions for this column are encouraged and should be forwarded to [email protected].
© 2008. From Surgical Oncology and Breast Services, Morehouse School of Medicine, Atlanta, GA. Send correspondence and reprint requests for J Natl Med Assoc. 2008;100:703–704 to: Dr. Harvey L. Bumpers, Professor of Surgery, Director of Surgical Oncology and Breast Services, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310; phone: (404) 616-2509; fax: (404) 616-1417; e-mail: [email protected]
D
r. Harvey Bumpers, professor of Surgery at Morehouse School of Medicine, Atlanta, GA, recently received two peer-review research awards from the Department of Defense and National Institutes of Health totaling nearly $1 million over three years.
Grant # 1 Department of Defense grant BC074381. This is an “Idea Award” with Bumpers as the principal investigator. His coinvestigators are Vincent Bond, PhD, and Ming-Bo Huang, MD. Title. Effects of a Viral Peptide (Nef) on Growth and Metastasis of Human Breast Cancer Description. This study will assess the ability of a novel peptide, Nef M1, to inhibit the growth and metastasis of breast cancer xenografts derived from cell lines and surgical specimens and implanted in severe combined immunodeficient (SCID) mice. This three-year award was issued on December 25, 2007 in the amount of $420,000 in total direct and indirect costs. Translational benefit of this research. By using this peptide to bind and replace the natural ligand for the cxcr-4 receptors on breast cancer cells, apoptosis can be induced within the tumor. This has been demonstrated both in human breast cancer cell lines and tumors derived from those cell lines. Bumpers was one of the first investigators in the world to develop the capability of propagating human surgical specimens of human breast cancer in SCID mice and demonstrated that this can be studied for both tumor engraftment and patterns of metastasis. This can potentially translate to adjuvant or combination therapy for breast cancer. The grant will enable the investigators to study the effect of this peptide on the primary growth of breast cancer as well as its ability to inhibit metastasis, specifically evaluating spread of disease to the liver and lungs. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
Grant # 2 Morehouse School of Medicine (MSM) & the University of Alabama–Birmingham Cancer Center (UABCCC) Partnership, National Institutes of Health U542-U54CA118948 This grant funds a partnership between MSM and UABCCC. Each institution is represented by a project or pilot grant principal investigator. The principal investigators on this grant are Dr. Upender Manne at UAB and Bumpers at MSM. (Cooperative cancer initiatives between these institutions have been underway for several years, and this award is the culmination of Bumpers’ lifelong interest in this area and this productive joint venture. Title. Predictive Molecular Markers of Colorectal Cancer of African-American Patients Description. The studies proposed in this project will identify potential prognostic phenotypic molecular markers of African Americans with colon cancer. This three-year award was approved on September 30, 2007, for a total direct and indirect cost of $423,000. Translational benefit of this research. In preliminary studies, Manne has shown that colorectal cancer in some African Americans manifests a preponderance of certain tumor markers. There was a strong correlation with the response to 5FU-based chemotherapy (5FU + leucovorin or 5FU + leucovorin + oxaliplatin), tumor phenotypes (Bcl-2, Bax, p53, etc.) and survival (in AfriVOL. 100, NO. 6, JUNE 2008 703
HARVEY L. BUMPERS, MD, FACS
can Americans, that was different from the same treatment algorithms utilized in Caucasians). Based on this preliminary research, the chemotherapy regimens used in Caucasians to treat colorectal cancers, sporadic stageII and -III, may actually be detrimental to survival in African Americans with similar phenotypic tumors and vice versa. Thus, this research could lead to routine evaluation of tumor phenotypes in African Americans with colorectal cancer, and therapy can be tailored specifically to those tumors based upon the known response patterns of these agents. At the present time, due to the lack of minority patients’ recruitment and participation in trials, it is assumed that all outcomes for treatment will be the same for African Americans and Caucasians with similar cancer diagnoses, and preliminary data suggest that this may not be the case. *** Bumpers was born in Mobile, AL, in 1956, attended Trinity College in Hartford, CT, from 1974–1978, graduating with a BS in biology followed by his MD degree with distinction in research from the University of Rochester in 1982. His surgical residency at the State University of New York at Stonybrook from 1982–1989 included two years as a cancer research fellow under Dr. Herbert Hoover. This was followed by a two-year clinical surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, NY. He then joined the faculty at the State University of New York at Buffalo as assistant professor of surgery from 1991–1996, and during that period he spent committed research time in the laboratory of Dr. Richard B. Bankert, who was the director of immunology at Roswell Park Cancer Institute. In 1996, Bumpers assumed the position of vice chairman of surgery and associate program director in surgery at MSM, where he remains today. Bumpers is certified by the American Board of Surgery with added qualifications in gastrointestinal endoscopic surgery. He is a faculty member of Alpha Omega Alpha; a fellow of the American College of Surgeons;
and a member of the American Association for Cancer Research, the Society of Surgical Oncology, the American Society of Clinical Oncology, the Society of American Gastrointestinal Endoscopic Surgeons, the Association for Academic surgery, the Society of Black Academic Surgeons and the Surgical Section–National Medical Association, among many others. He has been selected as Physician of the Year at Grady Hospital and has earned the Surgical Residency Teacher’s Award at Morehouse as well as the Teaching Excellence Award granted by the senior class at SUNY–Buffalo and the Student National Medical Association Teaching Award at SUNY–Buffalo in 1996. Bumpers has published 42 manuscripts in peerreviewed journals, book chapters and numerous abstracts and presentations across the country in his areas of expertise of breast and colon cancer. He has mentored countless students and residents during his career. Bumpers was the first investigator in the world to successfully implant a human breast cancer into an animal (SCID) mouse model in which the tumor actually engrafted, grew and metastasized, thus providing a reproducible model to study both the engraftment of tumors as well as their patterns of metastasis. He holds two patents, one for the SCID mouse model noted above and another for the viral peptide, Nef, that is the subject of the Department of Defense award below. He recently received two peer-review grants: 1) Department of Defense grant BC 074381 for $420,000 over three years to study the “effects of a viral peptide (Nef) on growth and metastasis of human breast cancer in a SCID mouse model” with colleague Bond; and 2) an NIH partnership award between the UABCCC, MSM School of medicine and Tuskegee, NIH U542-U54CA118948, for $423,000 over three years to evaluate, “the predictive molecular markers of colorectal cancer for African American patients” with UAB colleague Manne. Bumpers is married to Shari Bumpers, and they have three children. Bumpers has been very active in the Atlanta community educating the population at large about cancer prevention and treatment.
We Welcome Your Comments
To photocopy, e-mail, post on Internet or distribute this or any part of JNMA, please visit www.copyright.com.
704 JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
The Journal of the National Medical Association welcomes your Letters to the Editor about articles that appear in the JNMA or issues relevant to minority healthcare. Address correspondence to [email protected].
VOL. 100, NO. 6, JUNE 2008